Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

New Global Head of Cardiovascular and Metabolic Diseases Research looks to apply new tools to address tough challenges.

A complex protein module keeps the liver’s biochemical factory running smoothly and at capacity.

Ask Alan Frohman how he found out that he had glaucoma, and he'll quickly tell you that there were no warning signs.

Marc Pelletier traveled from Cambridge, MA to Shanghai, China, to launch new lines of research for the treatment of cancers that are common in China.

For all too many people living with heart failure, hospitalizations are a recurring part of life, affecting the lives of both patients and their caregivers.

The Novartis Faculty of Scholars initiative connects academic researchers with deep knowledge and big ideas to scientists in its drug discovery labs.

Kristen Harrington-Smith discusses her work as Vice President and Head of CAR-T US at Novartis Oncology.

In October 2013, we created a new, full-time position to lead our CR efforts. Juergen Brokatzky-Geiger, formerly Global Head of Human Resources and a member of the Executive Committee, took on this role effective in February 2014.

Dr. Matchaba describes how his unique background can help guide the company’s access-to-medicine efforts.